177Lu-Dotatate therapy for patients with metastatic gastrointestinal neuroendocrine tumors: How to prepare your practice for optimal administration.

Conclusions While planning for the provision of 177Lu-Dotatate treatment may pose challenging coordination and implementation of new workflows, proper departmental and institutional preparation has enabled high quality patient care and safe delivery of a novel therapy using an unsealed source within a nuclear medicine department setting that is addressing an unmet clinical need for this patient population.

Source: Journal of Nuclear Medicine - May 23, 2016 Category: Nuclear Medicine Authors: Abbott, A., Kuzuhara, Y., Jacene, H., Sakellis, C., Andersen, E., Hilton, N., Sommers, R., Chan, J. A., Kulke, M. H., Van den Abbeele, A. D. Tags: MTA I: Technologist Posters Source Type: research